二、公司业绩亏损的风险 公司目前公司生产经营活动一切正常，市场环境、行业政策没有发生重大调 整，公司下属 SPD 及 IVD 业务、凝血相关生产试剂等生产研发正常开展，内部生 产经营秩序正常。 | 证券代码：603716 | 证券简称：塞力医疗 公告编号：2023-085 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 塞力斯医疗科技集团股份有限公司 关于股票价格波动暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票于2023年8月7 日、8月8日、8月9日连续三个交易日收盘价格涨幅偏离值累计超过20%，根据《上 海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。公司已于2023 年8月10日披露《股票交易异常波动公告》（公告编号：2023-084）。2023年8月 10日，公司股票再次涨停。鉴于近期公司股票价格波动较大，敬请广大投资者注 意投资风险，理性投资。现将相关风险提示如下： 一、二级市场交易风险 ...

| 证券代码：603716 | 证券简称：塞力医疗 公告编号：2023-084 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 塞力斯医疗科技集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票交易连续3 个交易日（2023年8月7日、8月8日、8月9日）收盘价格涨幅偏离值累计超过20%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 二、公司关注并核实的相关情况 针对本次股票交易异常波动情况，公司对有关事项进行核实，现将核实情况 说明如下： （一）生产经营情况 经公司自查，目前公司生产经营活动一切正常，市场环境、行业政策没有发 生重大调整，公司下属 SPD 及 IVD 业务、凝血相关生产试剂等生产研发正常开 展，内部生产经营秩序正常。不存在影响公司股票交易价格异常波动的重大事宜， 不存在应披露而未披露的重大信息。 （二）重大事项情况 经公司自查，并向控 ...

关于塞力斯医疗科技集团股份有限公司 股票交易异常波动问询函的回复函 塞力斯医疗科技集团股份有限公司： 实际控制人： 本公司于 2023 年 8 月 9 日收到《塞力斯医疗科技集团股份有限公司关于股 票交易异常波动的问询函》，经认真自查,现就有关情况回复如下: 截至目前,作为塞力斯医疗科技集团股份有限公司(以下简称"公司")的 控股股东,本公司不存在影响公司股票价格异常波动的重大事项;不存在在本次 股票交易异常波动期间买卖公司股票的情况;不存在其他应披露而未披露的重大 信息,包括但不限于重大资产重组、股份发行、重大交易类事项、业务重组、股 份回购、股权激励、破产重整、重大业务合作、引进战略投资者等重大事项。 2023 年 8 月 9 日 关于塞力斯医疗科技集团股份有限公司 股票交易异常波动问询函的回复函 塞力斯医疗科技集团股份有限公司: 本人于 2023 年 8 月 9 日收到《塞力斯医疗科技集团股份有限公司关于股票 交易异常波动的问询函》，经认真自查，现就有关情况回复如下： 作为塞力斯医疗科技集团股份有限公司（以下简称"公司"）的实际控制人， 本人不存在影响公司股票价格异常波动的重大事项；不存在在本次股票交易 ...

Group 1: Company Overview and Business Models - Seer Medical focuses on two main business models: Integrated IVD (In Vitro Diagnostics) and Integrated SPD (Supply Chain Management) [3][4] - Integrated IVD involves long-term contracts with medical institutions for providing diagnostic instruments and related services, while Integrated SPD expands to overall supply chain management for medical consumables [5][6] - In 2022, the revenue from Integrated IVD was approximately 1.041 billion CNY with a gross margin of 23.34%, while Integrated SPD generated around 688.85 million CNY with a gross margin of 9.96% [7] Group 2: Market Presence and Expansion Plans - The company collaborates with over 2,300 medical institutions across China, with more than 500 being medical institutions [9] - Future plans include expanding SPD services nationwide and establishing regional testing centers [10][11] - The company aims to increase its market share by developing multiple business models in the SPD sector, particularly in regions like Chongqing and Sichuan [25][28] Group 3: Financial Performance and Projections - In 2022, Seer Medical achieved a revenue of 690 million CNY, maintaining stability despite economic challenges [25] - The company has set a revenue target of 2.3 billion CNY for 2023, with significant contributions expected from various subsidiaries [28] - The accounts receivable as of the end of 2022 was 1.767 billion CNY, with a significant portion being recoverable [31] Group 4: Risks and Challenges - The company faces challenges with increasing accounts receivable and a rising debt-to-asset ratio, which reached 60% [30] - Management has implemented measures to improve cash flow and reduce bad debt risks, focusing on strengthening accounts receivable management [29][31] - The company emphasizes the importance of maintaining transparency and managing risks associated with its business operations [34]

| 证券代码：603716 | 证券简称：塞力医疗 公告编号：2023-057 | | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | 塞力斯医疗科技集团股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： http://roadshow.sseinfo.com/），中国证券报·中证网 （https://www.cs.com.cn/roadshow/yjsmh/） 会议召开方式：上证路演中心视频直播和网络互动、中证网路演中心网络 互动 投资者可于 2023 年 5 月 15 日（星期一）至 5 月 19 日（星期五）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@thaly.net.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年度报告，为便于广大投资者更全面深入 ...

Financial Performance - In Q1 2023, the company reported revenue of CNY 444.07 million, a decrease of 23.29% compared to the same period last year[5]. - The net profit attributable to shareholders was a loss of CNY 14.91 million, representing a decline of 170% year-on-year[5]. - The basic earnings per share were CNY -0.07, a decrease of 173.25% compared to the same period last year[5]. - In Q1 2023, the company reported a net loss of CNY 6,651,427.65, compared to a net profit of CNY 25,738,000.43 in Q1 2022, indicating a significant decline in profitability[28]. - The company’s total comprehensive loss for the period was CNY 7,511,690.31, compared to a comprehensive income of CNY 21,546,216.99 in the same quarter last year[28]. Revenue Breakdown - The IVD business revenue was CNY 296.80 million, accounting for 66.79% of total revenue, down 5.91 percentage points from the previous year[7]. - Total operating revenue for Q1 2023 was ¥444,069,353.53, a decrease of 23.3% compared to ¥578,884,225.92 in Q1 2022[26]. - The total revenue from operating activities was CNY 587,950,514.74, an increase from CNY 459,800,471.28 in the same period last year, reflecting a growth of approximately 27.8%[29]. Expenses and Costs - Total expenses increased by 3.81% year-on-year to CNY 108 million, primarily due to increased sales and management expenses[10]. - Total operating costs for Q1 2023 were ¥455,311,016.55, down 15.7% from ¥540,110,563.59 in Q1 2022[26]. - Research and development expenses for Q1 2023 amounted to ¥7,450,644.90, a decrease of 13.6% from ¥8,630,117.36 in Q1 2022[26]. Cash Flow and Liquidity - The company’s cash flow from operating activities was CNY 38.64 million, which is not comparable to the previous period[5]. - The company reported a net cash flow from operating activities increase due to higher sales receipts[19]. - The company experienced a net cash flow from operating activities of CNY 38,642,551.81, a recovery from a negative cash flow of CNY 117,248,727.93 in Q1 2022[30]. - The company’s cash and cash equivalents decreased to 270.29 million from 394.54 million year-over-year[22]. - The company’s cash and cash equivalents at the end of Q1 2023 were CNY 261,908,897.81, down from CNY 406,322,679.30 at the end of Q1 2022, representing a decrease of approximately 35.5%[30]. Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 3.74 billion, down 5.30% from the end of the previous year[6]. - Total assets decreased to ¥3,738,068,484.78 in Q1 2023 from ¥3,947,450,797.29 in Q1 2022, reflecting a decline of 5.3%[25]. - Total liabilities decreased by 34.67 million due to repayment of long-term borrowings[19]. - Total liabilities decreased to ¥2,246,130,033.44 in Q1 2023 from ¥2,450,479,523.67 in Q1 2022, a reduction of 8.3%[24]. - Current assets totaled ¥2,755,718,512.10 in Q1 2023, down from ¥2,950,562,653.79 in Q1 2022, a decrease of 6.6%[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 25,534[18]. - The largest shareholder, Shanghai Saihai Health Technology Co., Ltd., holds 25,042,470 shares, representing 12.30% of total shares[19]. Strategic Initiatives - The company is undergoing a strategic transformation towards medical intelligence, which has impacted revenue from traditional IVD business[6]. - The company received government grants totaling 364.60 million, contributing positively to other income[19].

Financial Performance - The net profit attributable to shareholders for 2022 was -154,417,230.00 CNY, with cumulative distributable profits amounting to 411,784,160.60 CNY[5] - The parent company reported a net profit of -58,385,751.04 CNY for 2022, with cumulative distributable profits of 314,868,620.89 CNY[5] - The company plans not to distribute cash dividends for the 2022 fiscal year and will not increase capital reserves[5] - The company's revenue for 2022 was approximately CNY 2.31 billion, a decrease of 11.19% compared to CNY 2.60 billion in 2021[23] - The net loss attributable to shareholders for 2022 was CNY 154.42 million, compared to a loss of CNY 49.51 million in 2021[23] - The net cash flow from operating activities was CNY 28.12 million, a significant improvement from a negative cash flow of CNY 133.52 million in 2021[23] - Total assets decreased by 8.06% to CNY 3.95 billion in 2022 from CNY 4.29 billion in 2021[25] - The company reported a significant increase in credit impairment losses due to delayed receivables, amounting to CNY 34.24 million for specific clients undergoing bankruptcy restructuring[26] - The gross profit margin for the IVD segment decreased by 1.49 percentage points to 45.10% in 2022[27] - The basic earnings per share for 2022 was -CNY 0.79, compared to -CNY 0.25 in 2021[30] - The weighted average return on equity was -10.98% in 2022, down from -3.09% in 2021[30] Operational Developments - The company reported a comprehensive range of medical technology services, including centralized procurement and logistics support for medical institutions[12] - The annual report highlighted a focus on molecular diagnostics and point-of-care testing (POCT) technologies, which are critical for enhancing diagnostic accuracy[13] - The company is actively pursuing the establishment of regional inspection centers to support tiered diagnosis and treatment policies, aiming to improve healthcare delivery in local communities[13] - The implementation of a smart supply chain management platform is expected to enhance operational efficiency and reduce costs for medical institutions[14] - The company is committed to achieving CE certification for its products, ensuring compliance with European market standards[13] - The report indicated a strategic emphasis on expanding the company's presence in the medical supply chain sector, particularly in the context of integrated management solutions[14] - The company aims to leverage big data for disease diagnosis and treatment, enhancing its capabilities in healthcare management and reimbursement systems[13] - The annual report noted a focus on research and development of diagnostic reagents and self-built testing methods in laboratories[14] - The company is exploring opportunities for mergers and acquisitions to strengthen its market position and expand its service offerings[12] Strategic Initiatives - The future outlook includes a commitment to enhancing the quality of medical services through innovative technologies and comprehensive management solutions[12] - The company is focusing on a dual business model of "SPD+IVD" to enhance its position as a comprehensive service provider in the smart hospital ecosystem[38] - The strategic plan includes expanding into upstream advanced in vitro diagnostic technologies and outpatient services, aiming to increase market share in the IVD sector[41] - The company aims to enhance customer retention by integrating its own products into existing client systems, thereby increasing revenue and profit continuity[41] - New projects in molecular diagnostics are being introduced to leverage existing resources and improve market share in this area[41] - The company is committed to optimizing its organizational structure and extending its industrial ecosystem to support business development[39] - The company has signed smart medical industry park projects in Chongqing and Liangshan, creating regional SPD project models to capture more market share through localized cooperation[43] - The company aims to build a broad market smart medical ecosystem by leveraging innovative technology, localized services, and channel advantages, responding to the expanding county-level medical market[45] - The company is actively promoting the construction of smart medical digital industry parks to assist in the digital transformation of grassroots medical health services[51] Market Trends and Challenges - The IVD industry in China is experiencing rapid growth due to increasing healthcare spending and an aging population, leading to a sustained demand for medical products and services[54] - The average cost proportion of medical consumables in hospitals with a revenue scale of 1 billion is between 23% and 25%, while hospitals with over 2 billion can reach 33% to 34%[58] - The SPD business is expected to see a continuous increase in demand over the next five years, driven by policy support and the need for refined management in hospitals[62] - The company is positioned as a leading player in the medical consumables market, benefiting from high barriers to entry and a competitive landscape dominated by large enterprises[62] - The company has established regional inspection centers to enhance the quality of medical services, integrating resources to reduce costs and improve testing quality for grassroots medical institutions[64] Governance and Compliance - The company has received a qualified audit opinion from Zhongzheng Zhonghuan Accounting Firm[4] - The board of directors and management have confirmed the accuracy and completeness of the annual report[6] - The company has not provided guarantees in violation of decision-making procedures[7] - The report includes a detailed description of potential risks that the company may face in the future[7] - The company has established a long-term mechanism to prevent fund occupation by controlling shareholders and related parties[140] - The board of directors held 14 meetings during the reporting period, ensuring compliance with governance standards[137] - The company received regulatory warnings from the Shanghai Stock Exchange on July 15, 2022, and was criticized for its management practices, including the actions of its former chairman and general manager[160] - On September 30, 2022, the company was issued a warning letter by the Hubei Securities Regulatory Bureau, which was recorded in the securities market integrity archive[161] - The company was subject to multiple disciplinary actions throughout 2022, including a public reprimand on November 3, 2022, for governance issues involving key executives[162] - In January 2023, the company received an order for rectification from the Hubei Regulatory Bureau, emphasizing the need to improve corporate governance and compliance with regulations[162] Human Resources and Talent Management - The total number of employees in the parent company is 295, while the main subsidiaries employ 1,179, resulting in a total of 1,474 employees[175] - The company has a diverse educational background among employees, with 46 holding postgraduate degrees and 494 having bachelor's degrees[175] - The company emphasizes a competitive and effective compensation policy to motivate employees, linking pay to performance and company results[177] - Training programs are organized to enhance employee skills and core competitiveness, including various training methods such as internal and external training[178] - The company is enhancing its talent acquisition strategy to ensure a supply of skilled professionals to meet the increasing demand in the smart healthcare market[130] Research and Development - The company is prioritizing research and development in innovative healthcare solutions to meet market demands[156] - The company has registered 17 new product certificates during the reporting period, increasing the total to 195[100] - The company is actively pursuing new technology development to improve its diagnostic capabilities[147] - The company is investing $50 million in new product development, focusing on innovative medical technologies[148] Future Outlook - The company plans to expand its market presence by entering three new regions in 2023, aiming for a 15% increase in market share[148] - The company has set a performance guidance for the next fiscal year, projecting a revenue increase of 20%[148] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach[148] - The company plans to recover 1 billion in accounts receivable in 2023, which will significantly alleviate financial pressure and enhance net profit margins[129]

Financial Performance - The company's operating revenue for Q3 2022 was approximately CNY 612.60 million, representing a year-on-year decrease of 2.48%[5]. - The net profit attributable to shareholders for Q3 2022 was a loss of CNY 6.69 million, compared to a profit of CNY 8.58 million in the same period last year, marking a decline of 684.65%[5][7]. - For the first nine months of 2022, the total revenue was CNY 1.76 billion, down 3.48% year-on-year due to the ongoing impact of the pandemic and contract terminations[7]. - Total operating revenue for the first three quarters of 2022 was CNY 1,762,497,864.80, a decrease of 3.46% compared to CNY 1,825,974,014.36 in the same period of 2021[24]. - The company's net profit for the first three quarters of 2022 was impacted by a credit impairment loss of CNY -27,621,805.10, compared to CNY -13,890,700.18 in the previous year[24]. - The net profit for Q3 2022 was CNY 16,478,299.16, a decrease of 19.5% compared to CNY 20,355,739.76 in Q3 2021[25]. - The total profit for Q3 2022 was CNY 27,693,271.83, down from CNY 31,093,128.40 in the same period last year, reflecting a decline of 11.5%[25]. - The operating profit for Q3 2022 was CNY 28,741,567.50, compared to CNY 31,746,879.44 in Q3 2021, indicating a decrease of 9.5%[25]. Assets and Liabilities - The total assets at the end of Q3 2022 were CNY 4.18 billion, a decrease of 2.64% compared to the end of the previous year[6]. - Cash and cash equivalents as of September 30, 2022, were CNY 261,866,405.66, a decrease from CNY 473,549,725.12 at the end of 2021[20]. - Total assets as of September 30, 2022, were CNY 4,180,328,732.37, a decrease from CNY 4,293,573,705.49 at the end of 2021[22]. - Total liabilities decreased to CNY 2,455,822,235.01 from CNY 2,550,662,118.81 at the end of 2021, reflecting a reduction of 3.72%[22]. - The company's equity attributable to shareholders was CNY 1,538,508,098.96 as of September 30, 2022, down from CNY 1,562,078,741.56 at the end of 2021[22]. Cash Flow - The company reported a cash flow from operating activities of CNY 93.99 million for the first nine months of 2022[6]. - The cash flow from operating activities for the first nine months of 2022 was CNY 93,998,800.15, a significant improvement from a negative cash flow of CNY -198,098,122.87 in the same period of 2021[30]. - The total cash inflow from operating activities for the first nine months of 2022 was CNY 1,925,750,719.47, compared to CNY 1,830,535,426.66 in 2021, representing an increase of 5.2%[29]. - The cash flow from investing activities for the first nine months of 2022 was negative at CNY -26,471,555.97, an improvement from CNY -138,015,120.50 in the same period of 2021[30]. - The cash flow from financing activities for Q3 2022 was negative at CNY -285,859,867.03, compared to a positive cash flow of CNY 164,792,623.38 in Q3 2021[30]. Expenses and Provisions - Sales expenses increased by CNY 10.59 million, primarily due to the rise in salaries and benefits for sales personnel related to the new business with Johnson & Johnson[8]. - Financial expenses rose by CNY 10.29 million, attributed to increased financing costs[8]. - The company experienced a significant increase in credit impairment provisions, which rose by 98.85% year-on-year, amounting to an additional CNY 13.73 million[8]. - Research and development expenses decreased by 34.95% due to reduced material input and testing costs[14]. - Research and development expenses for the first three quarters of 2022 were CNY 16,811,524.37, a decrease from CNY 25,843,322.03 in the same period of 2021, indicating a reduction of 34.93%[24]. Revenue Sources - The revenue from the Hubei Provincial Tumor Hospital's contracts decreased by approximately 10.22%, resulting in a loss of CNY 49.32 million[12]. - The revenue from the subsidiary Shandong Selis Medical Technology Co., Ltd. decreased by approximately 76.02%, resulting in a loss of CNY 57.22 million due to contract terminations[12]. - Total revenue for Q3 2022 was 2,578,446.09, a decrease from 3,578,063.73 in the same period last year[13]. Other Financial Metrics - Cash and cash equivalents decreased by 44.70% due to a reduction in bank deposits[13]. - Trade financial assets decreased by 95.33% primarily due to the redemption of wealth management products[13]. - Accounts receivable decreased by 72.53% as a result of reduced receivables[13]. - Prepayments increased by 80.42% due to an increase in advance payments for goods[13]. - Long-term equity investments decreased by 45.82% due to the transfer of some long-term investments to other equity instruments[13]. - The company reported a 263.63% increase in accounts payable due to increased settlements using notes payable[13]. - Investment income decreased by 76.35% primarily due to reduced investment losses[14]. - The company had a total of 19,331 common shareholders at the end of the reporting period[16].

Financial Performance - The company reported a half-year revenue of 1.2 billion RMB, representing a 15% increase compared to the same period last year[1]. - The company's operating revenue for the first half of 2022 was approximately ¥1.15 billion, a decrease of 4.00% compared to ¥1.20 billion in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2022 was approximately ¥1.68 million, down 48.51% from ¥3.26 million in the previous year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥680,476, a decrease of 46.02% compared to ¥1.26 million in the same period last year[21]. - The company reported a total revenue of 25,015.62 million RMB from the acquisition of Jingyang Teng, with a net profit of 1,029.09 million RMB, reflecting a significant contribution to overall performance[75]. - The company reported a total of 381.67 million in loan disputes, with no judgments made yet[107]. - The company reported a significant increase in revenue, achieving a total of 212.83 million RMB from loan disputes during the reporting period[105]. - The company reported a net profit of -10,184,964, indicating a significant decrease in profitability compared to the previous period[163]. User Growth and Market Expansion - User data indicates a growth in active users by 20%, reaching 500,000 users by the end of the reporting period[1]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share within the next two years[1]. - The company aims to expand its market presence through the dual business model of IVD and SPD, focusing on both internal and external growth drivers[51]. - The company is focusing on channel mergers, market expansion, and strategic cooperation to strengthen nationwide terminal channel coverage[82]. - The user base grew by 85% compared to the previous period, showcasing strong market demand[163]. Research and Development - Research and development expenses increased by 30%, totaling 150 million RMB, focusing on innovative medical technologies[1]. - The company is committed to developing new technologies and products in the field of in vitro diagnostics and molecular diagnostics[21]. - The company is investing in new technology development, with a budget allocation of 1,327,853.0 million for R&D initiatives[164]. - The company has built a strong development team focused on integrating IoT, blockchain, and AI technologies to support the transition to intelligent medical supply chain services[49]. - Research and development expenses decreased to CNY 13,914,378.73, down from CNY 18,111,647.95 in the same period last year[148]. Financial Position and Assets - The total assets at the end of the reporting period were approximately ¥4.27 billion, a decrease of 0.55% from ¥4.29 billion at the end of the previous year[21]. - The company's total assets at the end of the reporting period were approximately 1,602,136,5 RMB, showing a substantial asset base[179]. - The company's total liabilities decreased by 48.07% to ¥102,193,755.15, down from ¥196,808,883.01 in the previous year[66]. - The total equity attributable to shareholders decreased to CNY 1,551,893,776.71 from CNY 1,562,078,741.56[142]. - The company's cash and cash equivalents decreased by 47.32% to ¥249,456,876.79, down from ¥473,549,725.12 in the previous year[65]. Operational Efficiency and Cost Management - The company is focusing on enhancing its integrated operation services for medical testing and consumables through smart supply chain management[21]. - The company is implementing strategies to accelerate accounts receivable collection to improve cash flow, as the collection period has lengthened due to tightened medical insurance payments[60]. - The company is actively promoting the LeviCell™ system for liquid magnetic levitation cell sorting in the Chinese market, targeting leading research institutions and biotech companies[58]. - New strategies are being implemented to improve operational efficiency and reduce costs by approximately 10% over the next year[170]. - The company's operating costs decreased by 5.87%, from ¥941,919,577.53 to ¥886,647,573.20[62]. Risks and Challenges - The company has outlined various operational risks and corresponding mitigation strategies in the report[1]. - The company is facing risks from industry policy changes, particularly in medical insurance cost control and payment reform, which may lead to price reductions for certain reagent products[82]. - Increased market competition is anticipated as the industry matures, with more potential entrants and existing competitors improving their technology and service capabilities[82]. - The company is experiencing growing accounts receivable and funding pressure due to long payment cycles from major clients, which could lead to increased capital costs and reduced capital efficiency[83]. - Internal control and operational management risks are heightened due to rapid company growth and the complexity of post-merger integration[82]. Corporate Governance and Compliance - The board of directors has confirmed the authenticity and completeness of the financial report[1]. - There are no violations of decision-making procedures regarding external guarantees[1]. - The company has not proposed any profit distribution or capital reserve increase for the half-year period[87]. - The company has committed to ensuring that its compensation system for directors and senior management is linked to the execution of its performance compensation measures[101]. - The company received a criticism notice from the Shanghai Stock Exchange on July 25, 2022, due to non-compliance in the use and management of raised funds, leading to inaccurate performance forecasts for 2021[108]. Incentive Plans and Employee Engagement - The company plans to grant up to 5,053,530 restricted stocks as part of its incentive plan[89]. - The incentive plan aims to align the interests of employees with those of shareholders[89]. - The company has unlocked a total of 1,231,882 restricted shares, accounting for 0.60% of the total share capital[90]. - The first unlocking period for the restricted stock incentive plan has been achieved, with all conditions met for full unlocking[89]. - The company has not received any objections regarding the incentive plan from the public during the disclosure period[89].

债券代码：113601 债券简称：塞力转债 证券代码：603716 证券简称：塞力医疗 公告编号：2022-041 塞力斯医疗科技集团股份有限公司 关于参加 2022 年湖北辖区上市公司投资者集体接待日活动 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为便于广大投资者全面了解塞力斯医疗科技集团股份有限公司（以下简称 "公司"） 业绩、公司治理、经营状况、可持续发展等投资者所关心的问题， 加强公司与投资者之间的沟通交流，公司将参加由湖北省证监局、湖北省上市公 司协会与深圳市全景网络有限公司联合举办的"2022 年湖北辖区上市公司投资 者集体接待日暨 2021 年度业绩说明会"主题活动。现将有关事项公告如下： 本次集体接待日活动将通过深圳全景网络有限公司提供的网上平台，采取网 络远程的方式举行。投资者可以登录"全景路演"网站（http://rs.p5w.net/） 或关注微信公众号"全景财经"，或下载全景路演 APP，参与公司本次投资者网 上集体接待日活动。活动时间为 2022 年 6 月 16 日（星期四）13 ...